Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3071509 A
Publication typeGrant
Publication dateJan 1, 1963
Filing dateMar 9, 1961
Priority dateMar 9, 1961
Publication numberUS 3071509 A, US 3071509A, US-A-3071509, US3071509 A, US3071509A
InventorsRobert C O'neill
Original AssigneeStauffer Chemical Co
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
N-alkyl-nornicotine:nicotine antagonist
US 3071509 A
Abstract  available in
Images(1)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent Ofifice Patented Jan. 1, 1963 3,071,509 N-Atkrt-Noarstcornsnuutcornsn ANrAooNisr No Drawing. Filed Mar. 9, 1961, Ser. No. 94,446 4 flaims. (Cl. 167-55) The present invention is concerned with certain novel pharmaceutical dosage forms. In particular, it is concerned with unitary dosage forms of certain compounds which I have found exert a physiological response antagonistic to that of nicotine.

The present application is a continuation in part of my copending application Serial Number 3,718, filed on January 21, 1960, noW Patent No. 2,981,641.

Many persons who smoke tobacco desire to break the smoking habit, or at least to diminish the amount of smoking. The reasons for such desire are many and varied, any may be based on advice from a physician or purely on economic considerations. in any case, it has been the experience of numerous smokers, and particularly of very heavy smokers, that it is very difficult to give up the tobacco habit. There are also many persons upon whom the nicotine absorbed from smoked tobacco exerts an undesired effect, for example, upon blood pressure or gastric secretion.

The present invention provides a help to the solution of the above problems. According to the present invention, the smoker orally ingests a unitary dosage form of a nicotine antagonist.

The nicotine antagonists useful in the present invention are compounds which are chemically related to nicotine itself, but they differ from nicotine in that the methyl group present on the nitrogen atom in the 5- membered ring of nicotine has been replaced by a lower alkyl group containing from 2 to 8 carbon atoms. The compounds are, chemically, N-alkyl nornicotines. As examples of suitable alkyl groups, there may be mentioned ethyl, propyl, isopropyl, hexyl, isobutyl, octyl, and, preferably, allyl, which is an unsaturated alkyl group.

The antagonist may be used in the form of thefree base, but it is preferred to use it in the form of an acid addition salt. The salt may be of any non-toxic acid, for example, citric acid, m-alic acid, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, and the like.

When taken by the smoker, the nicotine antagonists of the present invention diminish the physiological responses elicited in the smoker by nicotine and the related alkaloids absorbed from the smoke.

On the average, about 3 to 4 mgm. of nicotine are absorbed from the puffed smoke of an average cigarette. The smoke of a 10 gram cigar may contain some to more than 40 mgm. of nicotine. (See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 2nd Edition, 1956, p. 624.) The dosage of the antagonist should be of approximately the same order of magnitude as the amount of nicotine absorbed by the smoker. For the majority of smokers, the daily dosage will be from about 5 mgm. to about 250 mgrn. Particularly in the case of dosages toward the upper end of this range, the antagonist is preferably taken in split dosages, say three or four a day. Most desirably, the dosage is taken in the form of a sustained release capsule or tablet.

The unitary dosage forms of the present invention may be formulated in accordance with conventional practices well-known in the art. Any compatible inert excipient may be used. Examples include starch, milk sugar, calcium phosphate and the like. The preparation of sustained release dosage forms is also a well developed art, and such forms of the antagonist may be prepared in accordance With Well-known methods.

Example I Fifty mgm. of the citrate salt of N-alkyl nornicotine is mixed with 200 mgm. of starch, and the mixture is pressed into a tablet. One such tablet is taken at each of 3 meals daily by a smoker who averages forty cigarettes a day. The usual physiological responses due to smoking are diminished, and the craving for tobacco is decreased.

The foregoing example is given solely for the purposes of illustration and is not to be construed as limitation of the invention, many variations of which will occur to those skilled in the art Without departing from the spirit or scope thereof.

What is claimed is:

1. A unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornico-tine compounds containing from 2 to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids, together with a carrier.

2. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of a compound selected from the group consisting of N-alkyl nornicotine compounds containing from 2. to 8 carbon atoms in the alkyl group, and addition salts thereof with non-toxic acids.

3. A unitary dosage form suitable for oral ingestion, comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornicotine together with a carrier.

4. A sustained release unitary dosage form suitable for oral ingestion comprising from about 5 to about 250 mgm. of the citrate of N-allyl nornico-tine.

References Cited in the file of this patent UNITED STATES PATENTS 2,981,641 ONeill Apr. 25, 1961

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2981641 *Jan 21, 1960Apr 25, 1961Stauffer Chemical CoTobacco products
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4574151 *Aug 11, 1983Mar 4, 1986Peter Robin Broughton LawrenceAmine salts and products containing them
US4806356 *Apr 3, 1987Feb 21, 1989Shaw Alec S WTobacco product
US5122366 *Sep 25, 1989Jun 16, 1992The Arab Pharmaceutical CompanyAntismoke mouth wash comprising silver nitrate and propylene glycol
US5316759 *Mar 23, 1992May 31, 1994Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US5574052 *Apr 29, 1994Nov 12, 1996Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US5935975 *Apr 30, 1993Aug 10, 1999Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US7682633Mar 6, 2009Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US7682634Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical compositions
US8039459Jul 15, 2005Oct 18, 2011Universite LavalNicotinic receptor agonists for the treatment of inflammatory diseases
US8158156Jun 19, 2007Apr 17, 2012Alpharma Pharmaceuticals, LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8551983Jul 8, 2011Oct 8, 2013Universite LavalNicotinic receptor agonists for the treatment of inflammatory diseases
US8557804Jul 26, 2011Oct 15, 2013Universite LavalNicotinic receptor agonists for the treatment of inflammatory diseases
US8623418Dec 16, 2008Jan 7, 2014Alpharma Pharmaceuticals LlcPharmaceutical composition
US8685443Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8685444Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8846104Feb 13, 2012Sep 30, 2014Alpharma Pharmaceuticals LlcPharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247Feb 22, 2010Nov 4, 2014Alpharma Pharmaceuticals LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20080221085 *Jul 15, 2005Sep 11, 2008Universite LavalNicotinic Receptor Agonists for the Treatment of Inflammatory Diseases
US20080233197 *Jun 19, 2007Sep 25, 2008Francis Joseph MatthewsPharmaceutical compositions
US20090162450 *Mar 6, 2009Jun 25, 2009Alpharma Pharmaceuticals, Llc.Pharmaceutical composition
US20100143483 *Feb 22, 2010Jun 10, 2010Alpharma Pharmaceuticals, Llc.Pharmaceutical compositions
US20100151014 *Dec 16, 2008Jun 17, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100152221 *Dec 16, 2008Jun 17, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100266645 *Dec 16, 2008Oct 21, 2010Alfred LiangPharmaceutical compositions
US20110014280 *Jan 20, 2011Garth BoehmSequestering subunit and related compositions and methods
US20110027455 *Apr 23, 2010Feb 3, 2011Garth BoehmSequestering subunit and related compositions and methods
Classifications
U.S. Classification514/343, 131/270, 546/276.4
International ClassificationA61K45/00
Cooperative ClassificationA61K45/00
European ClassificationA61K45/00